| Name | ML-9 |
| Description | ML-9 suppresses MLCK, PKA, and PKC activity with Ki values of 4, 32, and 54 μM, respectively. ML-9 is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) activity. ML-9 causes autophagy by stimulating autophagosome formation and inhibiting their degradation. |
| In vitro | ML9 (50?μM; 1-4?hours) obviously enhances cleaved caspase-3 levels, reduced STIM1 protein levels by about 42%. ML9 (0-100?μM; 0-24?hours) has no reduction in cardiomyocyte viability, 50-100?μM obviously causes cell death [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.54 mM), Sonication is recommended. DMSO : 25 mg/mL (69.2 mM), Sonication is recommended.
|
| Keywords | viability | STIM1 | Myosin | MLCK | ML-9 | ML9 | ML 9 | Inhibitor | inhibit | caspase | cardiomyocyte | CalciumChannel | Calcium Channel | AKT |
| Inhibitors Related | Quadrol | Aceglutamide | 2,4,6-Tri-tert-butylphenol | Hyaluronic acid | L-Ascorbic acid | Ethyl linoleate | L-Ascorbic acid sodium salt | Methyl eugenol | 2-Nitrobenzoic acid | 2,3-Butanediol | Magnesium Chloride Hexahydrate | Magnesium sulfate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Neuroprotective Compound Library | Inhibitor Library | PPI Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |